Edwards Lifesciences (NYSE:EW) Price Target Raised to $105.00

27 Jul 2026, 02:01 by Teresa Graham · The Cerbat Gem

Edwards Lifesciences (NYSE:EW – Free Report) had its price target increased by JPMorgan Chase & Co. from $100.00 to $105.00 in a research report released on Friday,Benzinga reports. The brokerage currently has an overweight rating on the medical research company’s stock.

A number of other research firms have also weighed in on EW. Barclays reissued an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Wall Street Zen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Mizuho lifted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.55.

Check Out Our Latest Stock Analysis on Edwards Lifesciences

Edwards Lifesciences Trading Up 0.1%

EW opened at $82.67 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company’s 50 day simple moving average is $87.73 and its two-hundred day simple moving average is $83.88. Edwards Lifesciences has a 1-year low of $72.30 and a 1-year high of $96.29. The firm has a market capitalization of $47.60 billion, a price-to-earnings ratio of 47.51, a price-to-earnings-growth ratio of 2.07 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the prior year, the business earned $0.67 earnings per share. The business’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts expect that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,577 shares of company stock worth $3,855,527 in the last three months. 0.31% of the stock is owned by company insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently added to or reduced their stakes in EW. State Street Corp lifted its holdings in Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after buying an additional 371,892 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Edwards Lifesciences by 4.8% in the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock worth $1,857,934,000 after acquiring an additional 989,533 shares in the last quarter. Norges Bank acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $803,686,000. Morgan Stanley increased its position in shares of Edwards Lifesciences by 12.4% during the fourth quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock worth $623,544,000 after acquiring an additional 804,942 shares during the period. Finally, Marshall Wace LLP increased its position in shares of Edwards Lifesciences by 66.1% during the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after acquiring an additional 2,359,128 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences News Summary

Here are the key news stories impacting Edwards Lifesciences this week:

Positive Sentiment: Edwards Lifesciences beat Q2 estimates on both earnings and revenue, with sales rising 13.6% year over year to $1.74 billion, helped by strong demand for heart-valve products and growing adoption of mitral and tricuspid therapies.
Positive Sentiment: The company raised the low end of its full-year revenue outlook to $6.6 billion-$6.9 billion and also lifted its TAVR growth guidance, signaling management confidence in continued momentum.
Positive Sentiment: Analysts turned more constructive after the report: JPMorgan raised its price target to $105 and kept an overweight rating, while Leerink upgraded the stock to outperform with a $101 target.
Positive Sentiment: Commentary from Wall Street framed the quarter as evidence that Edwards remains a top medtech growth story, with its core TAVR franchise and newer structural heart therapies driving the upside.
Neutral Sentiment: The company’s updated Q3 and full-year EPS guidance was broadly in line with expectations, suggesting the current move is being driven more by sales strength and sentiment than by a major earnings surprise.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.